Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Tumor-derived extracellular vesicles: A potential novel liquid biomarker for pancreatic ductal adenocarcinoma.

Roman Oleksander Kowalchuk, Krishan Jethwa, Terence Tai Weng Sio et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14551

e14551 Background: Extracellular vesicles (EVs) are microscopic particles released by all cell types with a distinct fingerprint reflecting the cell of or...

Updated efficacy and safety results from the phase 2 study of timdarpacept in combination with tislelizumab in patients with classical Hodgkin lymphoma for whom prior anti–PD-1 therapy failed.

Ke-Shu Zhou, Shuling Hou, Yan Zhang et al. Jun 01, 2025 pp. 7041-7041 10.1200/jco.2025.43.16_suppl.7041

7041 Background: Timdarpacept (IMM01), a recombinant SIRPa-Fc fusion protein, can activate macrophages to enhance anti-tumor activity by blocking CD47-SIR...

Building a community-academic partnership to improve clinical trial access in southern Alabama.

SriDheeraja Kota, Aakash Desai, Tiffany Huggins et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13524

e13524 Background: In our efforts to identify and remove barriers to clinical trial enrollment in Alabama, we performed an updated analysis of our communi...

Phase II safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive follicular lymphoma.

Yan Huang, Yanyan Liu, Hongming He et al. Jun 01, 2025 pp. 7051-7051 10.1200/jco.2025.43.16_suppl.7051

7051 Background: Amulirafusp alfa (IMM0306) consists of anti-CD20 monoclonal antibody fused with the CD47 binding domain of SIRPα. It exerts potent anti-c...

An open-label single-center investigator-initiated exploratory clinical study in patients with refractory or recurrent solid tumors: R-ISV-FOLactis trial.

Ruojing Lv, Junmeng Zhu, Juanjuan Dai et al. Jun 01, 2025 pp. 2640-2640 10.1200/jco.2025.43.16_suppl.2640

2640 Background: Soft tissue sarcomas (STSs) are a highly complex group of tumors and the treatment still remains a challenge. Immunotherapy has become a...

Textbook outcomes after esophagectomy: A five-year of experience at a specialized centre in a developing country.

Sibgha Aimon, Muhammad Anas Bin Akhtar, Aamir Ali Syed et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16160

e16160 Background: A textbook outcome is a distinct measure that promotes better short- and long-term patient outcomes, improves the quality of care at in...

T-cell exhaustion and pre-existing T-cell immunity in circulation as predictive biomarkers for immunotherapy in NSCLC patients.

Anastasia Xagara, Konstantina Vasilieva, George Christodoulopoulos et al. Jun 01, 2025 pp. 2553-2553 10.1200/jco.2025.43.16_suppl.2553

2553 Background: Pre-existing cancer-antigen specific T-cells describe the endogenous adaptive immunity before any treatment that may represent a valuable...

Financial, social and time toxicity in early-phase cancer clinical trials: The PEARLER study.

Udit Nindra, Joanne Tang, Jun Hee Hong et al. Jun 01, 2025 pp. 11119-11119 10.1200/jco.2025.43.16_suppl.11119

11119 Background: Early phase clinical trials (EP-CTs) provide patients with access to novel therapeutics once standard of care options are exhausted or n...

A novel computational approach for survival prediction via fusion of whole-slide images and clinical data.

Chen Li, Guoqing Li, Xieqiao Yan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15119

e15119 Background: Annotations free survival prediction based on whole-slide-images(WSIs) requires diverse semantic information extraction ranging from th...

Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.

Marcelo Pitombeira de Lacerda, Meletios Athanasios Dimopoulos, Ludek Pour et al. Jun 01, 2025 pp. 7548-7548 10.1200/jco.2025.43.16_suppl.7548

7548 Background: Renal impairment is a frequent complication in relapsed/refractory multiple myeloma (RRMM). Results from DREAMM-7 (NCT04246047) showed si...

A large language model (LLM)-based multi-agent framework for risk stratification and treatment recommendations in localized prostate cancer (locPCa).

Umair Ayub, Syed Arsalan Ahmed Naqvi, Salman Ayub Jajja et al. Jun 01, 2025 pp. 5108-5108 10.1200/jco.2025.43.16_suppl.5108

5108 Background: We previously proposed a hybrid framework combining LLMs and rule based algorithm (RBA) for automating risk stratification in locPCa. Her...

Comparison of predictive models in women with advanced epithelial ovarian cancer triaged to primary debulking or neoadjuvant chemotherapy.

Shalini Rajaram, Lakhwinder Singh, Amrita Gaurav et al. Jun 01, 2025 pp. 5547-5547 10.1200/jco.2025.43.16_suppl.5547

5547 Background: Triaging women with advanced epithelial ovarian cancer (AEOC) into primary debulking surgery (PDS) or neoadjuvant chemotherapy (NACT) rem...

Niraparib plus PD-1 inhibitor for patients previously treated with immune checkpoint inhibitor for solid tumors with homologous recombination repair gene mutation (IMAGENE): A phase II basket study.

Taigo Kato, Takahiro Kojima, Masaki Shiota et al. Jun 01, 2025 pp. 2613-2613 10.1200/jco.2025.43.16_suppl.2613

2613 Background: Prior clinical trials have established the effectiveness of poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) or immune checkpoint in...

Strategies to achieve racial equity in cardio-oncology care for women with ovarian cancer.

Mina Fattah, Faisal Alali Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24028

e24028 Background: Ovarian cancer (OC) remains the most lethal gynecologic malignancy, despite significant advancements in treatment that have led to impr...

A monocentric analysis of ESCAT gene actionability detection in non-specific molecular profile (NSMP) endometrial cancer.

Floriana Camarda, Luca Mastrantoni, Chiara Parrillo et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17634

e17634 Background: The non-specific molecular profile (NSMP) subtype accounts for 50% of endometrial carcinoma (EC). It's a heterogeneous group of tumors,...

Irinotecan liposome combined with anlotinib as second-line treatment in patients with small cell lung cancer (SCLC).

Jialei Wang, Yina Wang, Jinghui Lin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20105

e20105 Background: Irinotecan is one of the options for the second-line treatment of SCLC. Liposomal irinotecan can specifically target tumor areas due to...

Real-world treatment patterns in patients with metastatic bladder cancer: A cross-regional analysis.

Aime Giorlando, Tiago Costa de Padua, Sheila Mpima et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23321

e23321 Background: Approximately 5% of patients are diagnosed with metastatic bladder cancer (mBC), and about half relapse after cystectomy. The treatment...

Estimating the access to psychotherapy and psychological support for cancer patients in Nigeria: A national study.

Sampson Chinonso Ipiankama, Runcie C.W. Chidebe, Maria-Chidi Christiana Onyedibe et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24068

e24068 Background: Cancer is a leading cause of psychiatric disorders, including depression, anxiety, delirium, distress, sexual dysfunction, and sleep di...

A multi-level qualitative exploration of factors influencing breast and cervical cancer screening uptake in Nepal.

Nithya Krishnamurthy, Bandana Paneru, Priyanka Timsina et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13858

e13858 Background: The global cancer burden disproportionately impacts low- and middle-income countries. In Nepal, breast and cervical cancer are the two...

Understanding tobacco use and cessation challenges amongst patients with lung cancer: Elucidating demographics and the role of social networks.

Arnav Pemmaraju, Melissa Francoise Neumann, Sheeja Rajan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22612

e22612 Background: Continued use of combustible tobacco after lung cancer diagnosis leads to worse morbidity and mortality. Unfortunately, smoking prevale...

Risk assessment and development of a machine learning–based prediction model for survival in patients with medulloblastoma.

Yu Su, Kaiwen Deng, Tao Jiang et al. Jun 01, 2025 pp. 10061-10061 10.1200/jco.2025.43.16_suppl.10061

10061 Background: While clinical risk factors have long guided medulloblastoma (MB) treatment, the significance of genetic events in therapeutic strategie...

First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase.

Cesar Augusto Perez, Linda R. Mileshkin, Saana D'Alonzo et al. Jun 01, 2025 pp. 3033-3033 10.1200/jco.2025.43.16_suppl.3033

3033 Background: B7-H4 is a transmembrane glycoprotein in the B7 superfamily with limited expression in normal tissue but is upregulated in solid tumors i...

Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: A meta-analysis.

Ana Paula Bedin, Gabriela Maffezoli, Pedro Silva et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20558

e20558 Background: Non-small cell lung cancer (NSCLC) is considered a significant health concern due to its high prevalence and frequently diagnosed at an...

The use of circulating tumor DNA (ctDNA) to evaluate need for additional targeted therapies in HER2 positive metastatic breast cancer (MBC).

Surbhi Warrior, Diana Alexandra Jaber, Natalie Knox Heater et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13003

e13003 Background: HER2+ MBC is an aggressive form of breast cancer. There have been significant advances in HER2 targeted therapies, but progression free...

Endoscopic submucosal dissection with adjuvant chemotherapy for early gastric cancer: Unnecessary complexity or added benefit? A real-world data analysis.

Haifeng Zhang, Shiya Zheng Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16132

e16132 Background: Endoscopic submucosal dissection (ESD) has become a standard treatment for early gastric cancer (EGC), offering high en bloc resection...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page